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Background:  Septal myectomy remains the gold-standard for symptomatic, medically-refractory patients with hypertrophic obstructive 
cardiomyopathy (HCM). Early post-myectomy, patients may demonstrate a high, late-peaking, mid-ventricular velocity (MVV). Whether 
presence of a high early post-operative MVV adversely affects downstream symptoms and mortality is unknown.
methods:  Transthoracic echocardiography (TTE) within 1 week of myectomy was reviewed for myectomies between 2003-2012 (n=1444). 
A high MVV was defined as a late-peaking, mid-ventricular velocity >2.2 m/s in the absence of left ventricular outflow tract (LVOT) 
obstruction. Patients with MVV were age- and gender- matched in a 2:1 fashion to myectomy patients without postop MVV. Symptoms and 
mortality were ascertained by medical record review and post-operative survey. Kaplan Meier survival curves were assessed via log-rank 
test.
results:  70 patients (5%) had a post-myectomy MVV (age 53.3±13.6 y, 50% male). There was no difference in pre-operative maximal 
LVOT gradient between MVV cases and matched controls. Median post-operative follow-up for patients with MVV was 0.2 (IQR 0.04-3.05) 
years vs. 1.02 (IQR 0.12-3.24) years for controls (P=0.045). There were no early perioperative deaths for either group. In late follow-up, 
there were no deaths in any of the MVV cases vs. 3 for HCM controls, median time to death 1.9 years, log rank P=0.25. Follow-up inclusive 
of symptom assessment >60 days post-operatively was available in 98 patients (47%), with no difference in loss to follow-up. There was 
no difference in post-operative NYHA class III/IV symptoms for these patients (21% for MVV cases vs. 19% for controls, P=0.77). Late TTE 
(>60 days post-op) was available for 11 MVV patients. Late TTE demonstrated resolution of MVV in 7 patients (64%); MVV fell from 38±13 
mmHg to 14±16 mmHg, P=0.69 given small sample size.
conclusion:  In HCM patients undergoing septal myectomy, an early, late-peaking, high MVV post-op does not carry adverse prognosis or 
portend worse symptomatic outcomes. In the majority of patients, MVV resolves on late TTE and likely reflects transient hyperdynamic left 
ventricular function as opposed to true obstruction.
